Moleculin Biotech Inc

MBRX

Company Profile

  • Business description

    Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company’s Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

  • Contact

    5300 Memorial Drive
    Suite 950
    HoustonTX77007
    USA

    T: +1 713 300-5160

    E: [email protected]

    https://www.moleculin.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    17

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,757.9013.20-0.15%
CAC 407,643.6740.06-0.52%
DAX 4023,265.71168.94-0.72%
Dow JONES (US)42,226.4610.660.03%
FTSE 1008,841.567.530.09%
HKSE23,710.69269.61-1.12%
NASDAQ19,499.8021.29-0.11%
Nikkei 22538,885.15348.410.90%
NZX 50 Index12,627.3212.03-0.10%
S&P 5005,982.670.05-0.00%
S&P/ASX 2008,531.2010.10-0.12%
SSE Composite Index3,388.811.400.04%

Market Movers